NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for V C Nannapaneni & Others
Natco Pharma surges 3% on positive outlook
The volumes were also positive as 11 lakh shares changed hands against the one-month daily traded average of 9 lakh NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Share Certificate
Buy NATCO Pharma; target of Rs 765: Geojit
Geojit is bullish on NATCO Pharma has recommended buy rating on the stock with a target price of Rs 765 in its research report dated June 21, 2023. NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
issue of duplicate share certificate Natco Pharma successfully completes USFDA inspection of Visakhapatnam facility
The inspection by the US drug regulator was conducted during the period from January 30 to February 3, 2023 NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO receives final approval for Tipiracil Hydrochloride and Trifluridine (generic for Lonsurf(r)) for the US market NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO's VIZAG FORMULATION FACILITY RECEIVES ESTABLISHMENT INSPECTION REPORT (EIR) Natco Pharma on the lookout for acquisition
Hyderabad-based drug-maker Natco Pharma targets 10-15 product launches a year NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
issue of duplicate share certificate